The combined use of CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression.
* For research use only. Not for use in diagnostic procedures.
For more information, visit Fujirebio.com.